Operationalizing Checkpoint Inhibitors in Urologic Practice Webcast (2022)

检查点抑制剂(CPIs)越来越多地用于泌尿系癌症的治疗,其中一些已被批准用于转移性和局限性疾病状态。泌尿科医生正在接受这些疗法,并考虑将它们引入自己的诊所和实践。集中患者的肿瘤治疗,简化联合治疗策略,提供基于价值和高效的癌症治疗是开始为泌尿科医生提供cpi的主要原因。本课程将讨论并提供一个结构化的方法,在繁忙的泌尿科实践中纳入检查点抑制剂。课程分为三个主要部分:适应症和导论;建立免疫肿瘤学(IO)项目;以及临床监测/副作用管理。参会者将全面了解免疫治疗患者的临床方面,以及项目支持的基础设施和人员要求。将特别关注后勤问题,如患者导航和教育,输液工作流程和财务/经济实践考虑。以案例为基础的不良反应管理部分将提出关键的回家信息,以改善泌尿科医生围绕这个问题的舒适度。

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Astellas
AstraZeneca
Bristol Myers Squibb
Exact Sciences
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lantheus Medical Imaging
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Genzyme

Target Audience

  • Urologists
  • Residents

Learning Objectives

At the conclusion of this course, participants will be able to:

  1. Discuss how to develop a structured approach for administering checkpoint inhibitors in urologic practice as part of a structured program.
  2. Manage adverse events from checkpoint inhibitors
  3. Identify practice implications of implementing a checkpoint inhibitor program
Course summary
Available credit:
  • 2.00AMA PRA Category 1 Credit™
  • 2.00Non-Physician Participation
Course opens:
05/18/2022
Course expires:
05/18/2023
Rating:
0

Education Council Disclosures

Education Council Disclosures 2021

COI Review Work Group Disclosures

COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated.

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Gautam Jayram, MD

has afinancial relationship (Consultant or Advisor (Oncology)) with Photocure; .
has afinancial relationship (Consultant or Advisor (Oncology)) with UroGPO; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Bristol Myers Squibb; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Tempus; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Merck; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Blue Earth; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Exact Sciences; .
has afinancial relationship (Scientific Study or Trial (Oncology)) with Janssen; .
has afinancial relationship (Consultant or Advisor (Oncology)) with AstraZeneca; .
Faculty(s)

Gordon Brown, DO

has a与辉瑞建立财务关系(顾问或顾问(肿瘤学)); .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Watson; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Sanofi-Aventis; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Astellas; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Johnson and Johnson; .
has afinancial relationship (Consultant or Advisor (Oncology)) with merck; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Genomic Health; .

Neal Shore, MD

has afinancial relationship (Consultant or Advisor (Oncology)) with Genesis Care; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Tolmar; .
has a与Pacific Edge的财务关系(咨询或顾问(肿瘤学)); .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Janssen; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Propella; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Foundation Medicine; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Boston Scientific; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Myovant; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Urogen; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Merck; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Phosphorus; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Bayer; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Sanofi Genzyme; .
has afinancial relationship (Consultant or Advisor (Oncology)) with GConcology; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Clovis Oncology; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Abbvie; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Guardant; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Astra Zeneca; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with emdSeronoMerck; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Urogen; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Myriad; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Sesen Bio; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Astellas; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Invitae; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Exact Imaging; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Amgen; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Genomic Health; .
has afinancial relationship (Scientific Study or Trial (Specialty Not Specified)) with Genentech; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Cold Genesys; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with MDxHealth; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Exact Sciences; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with dendreon; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Nymox; .
has afinancial relationship (Consultant or Advisor (Oncology)) with FerGene; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Bristol Myers Squibb; .
has afinancial relationship (Consultant or Advisor (Oncology)) with Moivant; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with Pfizer; .
has afinancial relationship (Consultant or Advisor (Specialty Not Specified)) with AstraZeneca; .

METHOD OF PARTICIPATION:

Learners will participate in this online educational activity by viewing the webcast, completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2022
Expiration Date: May, 2023

ACCREDIDATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring material for a maximum of 2.0AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified forAMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


AUA PARTICIPANT INFORMATION & POLICIES

DISCLAIMER:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

CONSENT TO USE OF PHOTOGRAPHIC IMAGES:

Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

AUDIO, VIDEO AND PHOTOGRAPHIC EQUIPMENT:

与会者禁止在本会会议室内使用音频、视频和其他摄影记录设备。

REPRODUCTION PERMISSION:

未经作者和美国泌尿学会的书面许可,禁止复制本课程的书面材料。世界杯英格兰vs伊朗波胆预测

SPECIAL ASSISTANCE/ DIETARY NEEDS:

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 2.00AMA PRA Category 1 Credit™
  • 2.00Non-Physician Participation
Pleaseloginorregisterto take this course.